In addition, in a retrospective cohort study, obesity might be a risk factor of cardiotoxicity in HER2+ BC patients receiving trastuzumab, indicating the necessity to prevent cardiotoxicity when receiving this regimen for patients with obesity and other risk factors (149). Here, ERBB2 is linked to breast cancer.